Lexicon Pharmaceuticals | LXRX - Umsatzkosten





Umsatzkosten Veränderung Datum
Abbott USD 5.94B 642M 2026-06
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
AstraZeneca USD 2.52B 2.73B 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Illumina USD 389M 19M 2026-06
Insmed USD 69.29M 19.79M 2026-06
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
J&J USD 8B 67M 2026-06
Lexicon Pharmaceuticals USD 201K 191K 2025-12
MacroGenics USD 9.53M 585K 2026-03
MannKind USD 34.21M 5.38M 2026-06
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Novartis USD 3.71B 251M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Thermo Fisher Scientific USD 7.54B 577M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
United Therapeutics USD 99.5M 33.9M 2026-06
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12